|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T,
Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et
al: Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2016:
A systematic analysis for the global burden of disease study. JAMA
Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takeuchi C, Yamamichi N, Shimamoto T,
Takahashi Y, Mitsushima T and Koike K: Gastric polyps diagnosed by
double-contrast upper gastrointestinal barium X-ray radiography
mostly arise from the Helicobacter pylori-negative stomach with low
risk of gastric cancer in Japan. Gastric Cancer. 20:314–321. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu G, Torres J, Hu N, Medrano-Guzman R,
Herrera-Goepfert R, Humphrys MS, Wang L, Wang C, Ding T, Ravel J,
et al: Molecular characterization of the human stomach microbiota
in gastric cancer patients. Front Cell Infect Microbiol. 7:3022017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen L, Xu JM, Feng FY, Jiao SC, Wang LW,
Li J, Guan ZZ, Qin SK, Wang JJ, Yu SY, et al: Trastuzumab in
combination with chemotherapy versus chemotherapy alone for
first-line treatment of HER2-positive advanced gastric or
gastroesophageal junction cancer: A Phase III, multi-center,
randomized controlled trial, Chinese subreport. Zhonghua Zhong Liu
Za Zhi. 35:295–300. 2013.(In Chinese). PubMed/NCBI
|
|
7
|
Galdy S, Cella CA, Spada F, Murgioni S,
Frezza AM, Ravenda SP, Zampino MG and Fazio N: Systemic therapy
beyond first-line in advanced gastric cancer: An overview of the
main randomized clinical trials. Crit Rev Oncol Hematol. 99:1–12.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bang YJ, Van CE, Feyereislova A, Chung HC,
Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al:
Trastuzumab in combination with chemotherapy versus chemotherapy
alone for treatment of HER2-positive advanced gastric or
gastro-oesophageal junction cancer (ToGA): A phase 3, open-label,
randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mellman I: Immunotherapies definition.
Dictionary.com. Retrieved 2009-06-02. Nature. 480:480–489. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Masihi KN: Fighting infection using
immunomodulatory agents. Expert Opin Biol Ther. 1:641–653. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Copp J, Xie WD, Zhang C and Berglin J:
Immunotherapy and cell therapy for cancer. CJPT. 30:87–94.
2016.
|
|
12
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Douglas H and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Walker LS: Treg and CTLA-4: Two
intertwining pathways to immune tolerance. J Autoimmun. 45:49–57.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dolan DE and Gupta S: PD-1 pathway
inhibitors: Changing the landscape of cancer immunotherapy. Cancer
Control. 21:231–237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jacob JA: Cancer immunotherapy researchers
focus on refining checkpoint blockade therapies. JAMA.
314:2117–2119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ipilimumab, . https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
|
|
23
|
Hellmann MD, Ott PA, Zugazagoitia J, Ready
NE, Hann CL, De Braud FG, Antonia SJ, Ascierto PA, Moreno V, Atmaca
A, et al: Nivolumab (nivo) ± ipilimumab (ipi) in advanced
small-cell lung cancer (SCLC): First report of a randomized
expansion cohort from CheckMate 032. J Clin Oncol. 35:85032017.
View Article : Google Scholar
|
|
24
|
ClinicalTrials.gov, . An efficacy study in
gastric and gastroesophageal junction cancer comparing ipilimumab
versus standard of care immediately following first line
chemotherapy. https://clinicaltrials.gov/ct2/show/NCT01585987
|
|
25
|
Tremelimumab, . https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
|
|
26
|
Ralph C, Elkord E, Burt DJ, O'Dwyer JF,
Austin EB, Stern PL, Hawkins RE and Thistlethwaite FC: Modulation
of lymphocyte regulation for cancer therapy: A phase II trial of
tremelimumab in advanced gastric and esophageal adenocarcinoma.
Clin Cancer Res. 16:1662–1672. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scapin G, Yang X, Prosise WW, McCoy M,
Reichert P, Johnston JM, Kashi RS and Strickland C: Structure of
full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.
Nat Struct Mol Biol. 22:953–958. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bang YJ, Kang YK, Catenacci DV, Muro K,
Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, et al:
Pembrolizumab alone or in combination with chemotherapy as
first-line therapy for patients with advanced gastric or
gastroesophageal junction adenocarcinoma: Results from the phase II
nonrandomized KEYNOTE-059 study. Gastric Cancer. 22:828–837. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
ClinicalTrials.gov, . A study of
pembrolizumab (MK-3475) in participants with recurrent or
metastatic gastric or gastroesophageal junction adenocarcinoma
(MK-3475-059/KEYNOTE-059). https://clinicaltrials.gov/ct2/show/NCT02335411
|
|
32
|
Shitara K, Özgüroğlu M, Bang YJ, Di
Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic
C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously
treated, advanced gastric or gastro-oesophageal junction cancer
(KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial.
Lancet. 392:123–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
ClinicalTrials.gov, . A study of
pembrolizumab (MK-3475) versus paclitaxel for participants with
advanced gastric/gastroesophageal junction adenocarcinoma that
progressed after therapy with platinum and fluoropyrimidine
(MK-3475-061/KEYNOTE-061). https://clinicaltrials.gov/ct2/show/NCT02370498
|
|
34
|
ClinicalTrials.gov, . Study of
pembrolizumab (MK-3475) as first-line monotherapy and combination
therapy for treatment of advanced gastric or gastroesophageal
junction adenocarcinoma (MK-3475-062/KEYNOTE-062). https://clinicaltrials.gov/ct2/show/NCT02494583
|
|
35
|
Nivolumab, . https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
|
|
36
|
Le TD, Bendell JC, Calvo E, Kim JW,
Ascierto PA, Sharma P, Ott PA, Bono P, Jeffry D, Evans TRJ, et al:
Safety and activity of nivolumab monotherapy in advanced and
metastatic (A/M) gastric or gastroesophageal junction cancer
(GC/GEC): Results from the CheckMate-032 study. J Clin Oncol.
34:2016. View Article : Google Scholar
|
|
37
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boku N, Kang YK, Satoh T, Chao Y, Kato K,
Chung HC, Chen JS, Muro K, Kang WK, Yoshikawa T, et al: 617OA Phase
3 Study of nivolumab (Nivo) in previously treated advanced gastric
or gastroesophageal junction (G/GEJ) cancer: Updated results and
subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol.
28:2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
ClinicalTrials.gov, . A study of nivolumab
by itself or nivolumab combined with ipilimumab in patients with
advanced or metastatic solid tumors. https://clinicaltrials.gov/ct2/show/NCT01928394
|
|
40
|
Lee JY, Lee HT, Shin W, Chae J, Choi J,
Kim SH, Lim H, Won Heo T, Park KY, Lee YJ, et al: Structural basis
of checkpoint blockade by monoclonal antibodies in cancer
immunotherapy. Nat Commun. 7:133542016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Segal NH, Antonia SJ, Brahmer JR, Maio M,
Blake-Haskins A, Vasselli XL, Ibrahim RA, Lutzky J and Khleif S:
Preliminary data from a multi-arm expansion study of MEDI4736, an
anti-PD-L1 antibody. J Clin Oncol. 32:30022014. View Article : Google Scholar
|
|
43
|
Levy A, Massard C, Soria JC and Deutsch E:
Concurrent irradiation with the anti-programmed cell death ligand-1
immune checkpoint blocker durvalumab: Single centre subset analysis
from a phase 1/2 trial. Eur J Cancer. 68:156–162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
A phase 1b/2 study of MEDI4736 with
tremelimumab, MEDI4736 or tremelimumab monotherapy in gastric or
GEJ adenocarcinoma. https://clinicaltrials.gov/ct2/show/NCT02340975
|
|
45
|
Chung HC, Arkenau HT, Lee J, Rha SY, Oh
DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, et al: Avelumab
(anti-PD-L1) as first-line switch-maintenance or second-line
therapy in patients with advanced gastric or gastroesophageal
junction cancer: Phase 1b results from the JAVELIN solid tumor
trial. J Immunother Cancer. 7:302019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
ClinicalTrials.gov, . Avelumab in
metastatic or locally advanced solid tumors (JAVELIN Solid Tumor
JPN). https://clinicaltrials.gov/ct2/show/NCT01943461
|
|
47
|
Mohme M, Riethdorf S and Pantel K:
Circulating and disseminated tumour cells-mechanisms of immune
surveillance and escape. Nat Rev Clin Oncol. 14:155–167. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Stauss HJ, Morris EC and Abken H: Cancer
gene therapy with T cell receptors and chimeric antigen receptors.
Curr Opin Pharmacol. 24:113–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Patel JM, Dale GA, Vartabedian VF, Dey P
and Selvaraj P: Cancer CARtography: Charting out a new approach to
cancer immunotherapy. Immunotherapy. 6:675–678. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gill S, Maus MV and Porter DL: Chimeric
antigen receptor T cell therapy: 25 years in the making. Blood Rev.
30:157–167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang Q, Zhang Z, Peng M, Fu S, Xue Z and
Zhang R: CAR-T cell therapy in gastrointestinal tumors and hepatic
carcinoma: From bench to bedside. Oncoimmunology. 5:e12515392016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Novartis CAR-T cell therapy CTL019
receives FDA breakthrough therapy designation for treatment of
adult patients with r/r DLBCL. https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation
|
|
53
|
Lee YH and Kim CH: Evolution of chimeric
antigen receptor (CAR) T cell therapy: Current status and future
perspectives. Arch Pharm Res. Mar 4–2019.(Epub ahead of print).
View Article : Google Scholar
|
|
54
|
Brudno JN and Kochenderfer JN: Recent
advances in CAR T-cell toxicity: Mechanisms, manifestations and
management. Blood Rev. 34:45–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hege KM, Bergsland EK, Fisher GA,
Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH
and Sherwin SA: Safety, tumor trafficking and immunogenicity of
chimeric antigen receptor (CAR)-T cells specific for TAG-72 in
colorectal cancer. J Immunother Cancer. 5:222017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lonez C, Verma B, Hendlisz A, Aftimos P,
Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer
JB, et al: Study protocol for THINK: A multinational open-label
phase I study to assess the safety and clinical activity of
multiple administrations of NKR-2 in patients with different
metastatic tumour types. BMJ Open. 7:e0170752017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tchou J, Zhao Y, Levine BL, Zhang PJ,
Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey
SF, et al: Safety and efficacy of intratumoral injections of
chimeric antigen receptor (CAR) T cells in metastatic breast
cancer. Cancer Immunol Res. 5:1152–1161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang C, Wang Z, Yang Z, Wang M, Li S, Li
Y, Zhang R, Xiong Z, Wei Z, Shen J, et al: Phase I escalating-dose
trial of CAR-T therapy targeting CEA+ metastatic colorectal
cancers. Mol Ther. 25:1248–1258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li J, Li W, Huang K, Zhang Y, Kupfer G and
Zhao Q: Chimeric antigen receptor T cell (CAR-T) immunotherapy for
solid tumors: Lessons learned and strategies for moving forward. J
Hematol Oncol. 11:222018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Abrahao-Machado LF and Scapulatempo-Neto
C: HER2 testing in gastric cancer: An update. World J
Gastroenterol. 22:4619–4625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kurokawa Y, Matsuura N, Kimura Y, Adachi
S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN,
Takiguchi S, et al: Multicenter large-scale study of prognostic
impact of HER2 expression in patients with resectable gastric
cancer. Gastric Cancer. 18:691–697. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sheffield BS, Garratt J, Kalloger SE,
Li-Chang HH, Torlakovic EE, Gilks CB and Schaeffer DF: HER2/neu
testing in gastric cancer by immunohistochemistry: Assessment of
interlaboratory variation. Arch Pathol Lab Med. 138:1495–1502.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zulfiqar M, Bhalla A, Weindel M and
Shidham VB: Molecular diagnostics in esophageal and gastric
neoplasms. Clin Lab Med. 33:867–873. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Whilding LM and Maher J: ErbB-targeted CAR
T-cell immunotherapy of cancer. Immunotherapy. 7:229–241. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
A clinical research of CAR T cells
targeting HER2 positive cancer. https://clinicaltrials.gov/ct2/show/NCT02713984
|
|
66
|
ClinicalTrials.gov, . Treatment of
chemotherapy refractory human epidermalgrowth factor
receptor-2(HER-2) positive advanced solid tumors (CART-HER-2).
https://clinicaltrials.gov/ct2/show/NCT01935843
|
|
67
|
ClinicalTrials.gov, . Her2 and TGFBeta
cytotoxic T cells in treatment of Her2 positive malignancy
(HERCREEM). https://clinicaltrials.gov/ct2/show/NCT00889954
|
|
68
|
Wang L, Ma N, Okamoto S, Amaishi Y, Sato
E, Seo N, Mineno J, Takesako K, Kato T and Shiku H: Efficient tumor
regression by adoptively transferred CEA-specific CAR-T cells
associated with symptoms of mild cytokine release syndrome.
Oncoimmunology. 5:e12112182016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Guest RD, Kirillova N, Mowbray S, Gornall
H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kühlcke K,
et al: Definition and application of good manufacturing
process-compliant production of CEA-specific chimeric antigen
receptor expressing T-cells for phase I/II clinical trial. Cancer
Immunol Immunother. 63:133–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chalick M, Jacobi O, Pichinuk E, Garbar C,
Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J,
et al: MUC1-ARF-A novel MUC1 protein that resides in the nucleus
and is expressed by alternate reading frame translation of MUC1
mRNA. PLoS One. 11:e01650312016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Rajabi H, Hiraki M, Tagde A, Alam M,
Bouillez A, Christensen CL, Samur M, Wong KK and Kufe D: MUC1-C
activates EZH2 expression and function in human cancer cells. Sci
Rep. 7:74812017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Genitsch V, Zlobec I, Thalmann GN and
Fleischmann A: MUC1 is upregulated in advanced prostate cancer and
is an independent prognostic factor. Prostate Cancer Prostatic Dis.
19:242–247. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lee HK, Kwon MJ, Seo J, Kim JW, Hong M,
Park HR, Min SK, Choe JY, Ra YJ, Jang SH, et al: Expression of
mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer:
Comparison with EGFR-mutated lung cancer. Pathol Res Pract.
215:459–465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang MH, Sun R, Zhou XM, Zhang MY, Lu JB,
Yang Y, Zeng LS, Yang XZ, Shi L, Xiao RW, et al: Epithelial cell
adhesion molecule overexpression regulates epithelial-mesenchymal
transition, stemness and metastasis of nasopharyngeal carcinoma
cells via the PTEN/AKT/mTOR pathway. Cell Death Dis. 9:22018.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Maher J and Wilkie S: CAR mechanics:
Driving T cells into the MUC of cancer. Cancer Res. 69:4559–4562.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Warneke VS, Behrens HM, Haag J, Krüger S,
Simon E, Mathiak M, Ebert MP and Röcken C: Members of the EpCAM
signalling pathway are expressed in gastric cancer tissue and are
correlated with patient prognosis. Br J Cancer. 109:2217–2227.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
ClinicalTrials.gov, . CAR-T cell
immunotherapy in MUC1 positive solid tumor. https://clinicaltrials.gov/ct2/show/NCT02617134
|
|
78
|
ClinicalTrials.gov, . Study evaluating the
efficacy and safety with CAR-T for stomach cancer (EECSC).
https://clinicaltrials.gov/ct2/show/NCT02725125
|
|
79
|
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J,
Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An
immunogenic personal neoantigen vaccine for patients with melanoma.
Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Cheever MA and Higano CS: PROVENGE
(Sipuleucel-T) in prostate cancer: The first FDA-approved
therapeutic cancer vaccine. Clin Cancer Res. 17:3520–3526. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ribas A, Butterfield LH, Glaspy JA and
Economou JS: Current developments in cancer vaccines and cellular
immunotherapy. J Clin Oncol. 21:2415–2432. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Gilliam AD and Watson SA: G17DT: An
antigastrin immunogen for the treatment of gastrointestinal
malignancy. Expert Opin Biol Ther. 7:397–404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Park DJ, Thomas NJ, Yoon C and Yoon SS:
Vascular endothelial growth factor a inhibition in gastric cancer.
Gastric Cancer. 18:33–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Sundar R, Rha SY, Yamaue H, Katsuda M,
Kono K, Kim HS, Kim C, Mimura K, Kua LF and Yong WP: A phase I/Ib
study of OTSGC-A24 combined peptide vaccine in advanced gastric
cancer. BMC Cancer. 18:3322018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Watson SA, Michaeli D, Grimes S, Morris
TM, Robinson G, Varro A, Justin TA and Hardcastle JD: Gastrimmune
raises antibodies that neutralize amidated and glycine-extended
gastrin-17 and inhibit the growth of colon cancer. Cancer Res.
56:880–885. 1996.PubMed/NCBI
|
|
86
|
Smith AM, Justin T, Michaeli D and Watson
SA: Phase I/II study of G17-DT, an anti-gastrin immunogen, in
advanced colorectal cancer. Clin Cancer Res. 6:4719–4724.
2000.PubMed/NCBI
|
|
87
|
Brett BT, Smith SC, Bouvier CV, Michaeli
D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van
Someren N, Pounder RE and Caplin ME: Phase II study of
anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic
cancer. J Clin Oncol. 20:4225–4231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Gilliam AD, Watson SA, Henwood M, McKenzie
AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome
P and Michaeli D: A phase II study of G17DT in gastric carcinoma.
Eur J Surg Oncol. 30:536–543. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ajani JA, Hecht JR, Ho L, Baker J,
Oortgiesen M, Eduljee A and Michaeli D: An open-label,
multinational, multicenter study of G17DT vaccination combined with
cisplatin and 5-fluorouracil in patients with untreated, advanced
gastric or gastroesophageal cancer: The GC4 study. Cancer.
106:1908–1916. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Rocha-Lima CM, de Queiroz Marques Junior
E, Bayraktar S, Broome P, Weissman C, Nowacki M, Leslie M and
Susnerwala S: A multicenter phase II study of G17DT immunogen plus
irinotecan in pretreated metastatic colorectal cancer progressing
on irinotecan. Cancer Chemother Pharmacol. 74:479–486. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Gastrin 17 vaccine-Aphton, . Anti-gastrin
17 immunogen, G17DT. BioDrugs. 17:223–225. 2003.PubMed/NCBI
|
|
92
|
Zhao T, Zhao W, Chen Y, Liu L, Ahokas RA
and Sun Y: Differential expression of vascular endothelial growth
factor isoforms and receptor subtypes in the infarcted heart. Int J
Cardiol. 167:2638–2645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wada S, Tsunoda T, Baba T, Primus FJ,
Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic
cancer therapy with vaccination using epitope peptides derived from
human vascular endothelial growth factor receptor 2. Cancer Res.
65:4939–4946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ishizaki H, Tsunoda T, Wada S, Yamauchi M,
Shibuya M and Tahara H: Inhibition of tumor growth with
antiangiogenic cancer vaccine using epitope peptides derived from
human vascular endothelial growth factor receptor 1. Clin Cancer
Res. 12:5841–5849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Masuzawa T, Fujiwara Y, Okada K, Nakamura
A, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Osawa
R, et al: Phase I/II study of S-1 plus cisplatin combined with
peptide vaccines for human vascular endothelial growth factor
receptor 1 and 2 in patients with advanced gastric cancer. Int J
Oncol. 41:1297–1304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ishikawa H, Imano M, Shiraishi O, Yasuda
A, Peng YF, Shinkai M, Yasuda T, Imamoto H and Shiozaki H: Phase I
clinical trial of vaccination with LY6K-derived peptide in patients
with advanced gastric cancer. Gastric Cancer. 17:173–180. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
ClinicalTrials.gov, . Study of OTSGC-A24
vaccine in advanced gastric cancer. https://clinicaltrials.gov/ct2/show/NCT01227772
|
|
98
|
Valpione S and Campana LG: Immunotherapy
for advanced melanoma: Future directions. Immunotherapy. 8:199–209.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Stinchcombe TE: Unmet needs in squamous
cell carcinoma of the lung: Potential role for immunotherapy. Med
Oncol. 31:9602014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Dong M, Wang HY, Zhao XX, Chen JN, Zhang
YW, Huang Y, Xue L, Li HG, Du H, Wu XY and Shao CK: Expression and
prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr
virus-associated gastric carcinoma. Hum Pathol. 53:25–34. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Shinozaki-Ushiku A, Kunita A and Fukayama
M: Update on Epstein-Barr virus and gastric cancer (review). Int J
Oncol. 46:1421–1434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Bolm L, Käsmann L, Paysen A, Karapetis C,
Rades D, Wellner UF, Keck T, Watson DI, Hummel R and Hussey DJ:
Multimodal anti-tumor approaches combined with immunotherapy to
overcome tumor resistance in esophageal and gastric cancer.
Anticancer Res. 38:3231–3242. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Lazăr DC, Avram MF, Romosan I, Cornianu M,
Tăban S and Goldis A: Prognostic significance of tumor immune
microenvironment and immunotherapy: Novel insights and future
perspectives in gastric cancer. World J Gastroenterol.
24:3583–3616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cui J, Li L, Wang C, Jin H, Yao C, Wang Y,
Li D, Tian H, Niu C, Wang G, et al: Combined cellular immunotherapy
and chemotherapy improves clinical outcome in patients with gastric
carcinoma. Cytotherapy. 17:979–988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wang Y, Wang C, Xiao H, Niu C, Wu H, Jin
H, Yao C, He H, Tian H, Han F, et al: Adjuvant treatment combining
cellular immunotherapy with chemotherapy improves the clinical
outcome of patients with stage II/III gastric cancer. Cancer Med.
6:45–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhandossov O, Kaussova G and Koten A:
Combined treatment for gastric cancer: Immunological approach. Turk
J Gastroenterol. 29:151–156. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Hamanishi J, Mandai M, Ikeda T, Minami M,
Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S,
et al: Safety and antitumor activity of anti-PD-1 antibody,
nivolumab, in patients with platinum-resistant ovarian cancer. J
Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Stevanović S, Pasetto A, Helman SR,
Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff
CA, Rosenberg SA and Hinrichs CS: Landscape of immunogenic tumor
antigens in successful immunotherapy of virally induced epithelial
cancer. Science. 356:200–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zacharakis N, Chinnasamy H, Black M, Xu H,
Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al:
Immune recognition of somatic mutations leading to complete durable
regression in metastatic breast cancer. Nat Med. 24:724–730. 2018.
View Article : Google Scholar : PubMed/NCBI
|
